PARTNER 1 coordinator

 

NVGH logo

NVGH (Novartis Vaccine Institute for Global Health S.r.l., Siena, Italy) is a vaccine company created to develop effective and affordable vaccines for neglected infectious diseases of impoverished communities. Its current vaccine projects are all aimed at bacterial infections:  a bivalent conjugate vaccine against S. Typhi and S. Paratyphi A particularly for use in Asia, a vaccine for Nontyphoidal Salmonella (NTS) in Africa, a vaccine for Shigella and a vaccine for meningitis in Africa.

NVGH is co-located with Novartis Vaccines and Diagnostics in Siena, Italy, and has access to the human and physical resources of Novartis Vaccines. NVGH occupies purpose built laboratories that provide facilities for the production and purification of bacterial proteins and polysaccharides and for the immunological and functional evaluation of candidate vaccines.

Through its affiliation with Novartis Vaccines, NVGH has access to an impressive array of high technology equipment and expertise. Of particular relevance for this project is the proteomics facility that enables detailed analysis of proteins present in OMB and the FACS facility for analysing the binding of antibodies generated against OMB to the bacterial surface. Novartis Vaccines also provides the facilities required for daily operation including extensive computer facilities, library facilities, and the human resource facility with dedicated staff to facilitate exchange programs including obtaining visas, assistance with housing, language training, etc.

 

 

PARTNER 2

 

WTSI logo

The Wellcome Trust Sanger Institute (WTSI) is a research institute funded via a rolling 5 year grant of Euro 485M by the charity, Wellcome Trust. The WTSI main research areas are Human Genetics, Model Organism Genetics, Pathogens and Bioinformatics; these are underpinned by a number of core technologies and scientific support systems. The Institute employs over 850 FTE and has state of the art containment (CL2, 3) facilities for working with pathogens as well as animal facilities housing the largest collection of KO mice in any academic institution in the world. The WTSI also has a significant murine stem cell programme with an aim to make a collection of ES cells harbouring mutations in all mouse genes. The WTSI also has FACS, microscopy (light and EM) and Mass Spectroscopy capacity. Over 35 faculty work on site and large core teams support high throughput genotyping, large scale DNA sequencing and mouse genotyping programmes along with a Cancer Genome Project. Animal models are available for many infection challenges including Salmonella, influenza, Citrobacter, E. coli, C. difficile, Helicobacter, malaria, Streptococcus, Bordetella, Neisseria, etc. up to Containment Level 3.

 

 

PARTNER 3

 

STPHI logo

The Swiss Tropical and Public Health Institute (STPHI) is a public non-commercial organisation supported by the Swiss Federal Government and the Canton of Basel-Stadt. Its mandate is to contribute to health development at the local, national and international level through research, teaching and training and services. The STI is divided into specialist synergistic departments including research departments for Medical Parasitology/Infection Biology and for Public Health and Epidemiology, a competence centre for public and international health with a Pharmaceutical Medical Unit and a Medical and Diagnostic Services Department. The cornerstone for teaching and training activities is provided by STI's position as an associated institute of the University of Basel, complemented by its many international academic linkages and participation in training networks. Research activities in the fields of basic host-pathogen interactions at molecular, cellular and population levels as well as on health systems include: 1. developing new approaches for the design and delivery of subunit vaccines; 2. bringing new therapeutics and vaccines from the laboratory to clinical trials, 3. contributing to a better understanding and control of neglected diseases.

 

 

PARTNER 4

 

KEMRI logo

The Kenya Medical Research Institute (KEMRI) was established in 1979 under the Science and Technology (Amendment) Act; Under this Act, the Kenya Medical Research Institute was charged with the responsibility of carrying out health research, and its mandates under the Act are stated as follows:

 

1. Carry out research in the field of biomedical sciences;

2. Co-operate with other organisations and institutions with higher training programmes and on matters of relevant research;

3. Liaise with other research bodies within and outside Kenya carrying out similar research;

4. Disseminate research findings;

5. Co-operate with the Ministry of Health, the Ministry, for the time being responsible for research, the National Council for Science and Technology, and the Medical Science Advisory Committee on matters pertaining to research policies and priorities

 

The Centre for Microbiology Research is one of the eight centres of research spread across many region in Kenya and mandated by the Act of Parliament to do Medical research under the Ministry of Health. The Enterics Microbiology Laboratory (EML) involved in GENDRIVAX has mandate to perform research and dissemination of data in the following areas:

 

1. Surveillance and epidemiology of enteric pathogens – Salmonella, cholera, Shigella, E. coli and Klebsiella infections in hospitals and community.

2. Antimicrobial susceptibility testing and surveillance.

3. Molecular characterisation of bacterial resistance.

4. Co-ordinate the WHO Centres for Disease Control and Prevention (CDC) external quality assurance program on susceptibility testing.